Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SBI Holdings Inc    8473   JP3436120004

SummaryChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SBI Holdings Inc : Notice on Partial Transfer of Subsidiary Shares and the Resulting Extraordinary Income

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/30/2012 | 01:14pm CET

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the

whole or any part of the contents of this announcement.

SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488) OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock
Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board SBI Holdings, Inc. Yoshitaka Kitao

Chief Executive Officer

Japan, 30 March 2012

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Kenji Hirai, Mr Tomoya Asakura, Mr Takashi Okita, Mr Noriaki Maruyama, Mr Shumpei Morita, Mr Shinji Yamauchi, Mr Makoto Miyazaki, Mr Yoshimi Takahashi and Mr Masaki Takayanagi, the non-executive Directors are Mr Yasutaro Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura and Mr Hiroshi Tasaka and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Takeshi Natsuno and Mr Akihiro Tamaki.

March 30, 2012
SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488)

Notice on Partial Transfer of Subsidiary Shares and the Resulting Extraordinary Income

SBI Holdings, Inc. ("SBIH") hereby announces that it will transfer some of the shares its subsidiary holds in consolidated subsidiary SBI ALApromo Co, Ltd. (the company name is to be changed to SBI Pharmaceuticals Co., Ltd. on April 1, 2012; head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; "SBI ALApromo"). The shares will be transferred to multiple third parties. SBIH is expected to book an extraordinary income as a result of this share transfer.
1. Reasons for the transfer
SBI ALApromo, which obtained First-class Marketing Authorization in February 2012, is actively engaged in research and development of medicines, cosmetics and health foods using 5-aminolevulinic acid (ALA)* as a pharmaceutical company. As SBI ALApromo plans to accelerate development of new drugs utilizing ALA, the proceeds from this transfer will be allocated primarily for prior investments in the business. The transferees of the shares were determined in consideration of their ability to contribute to future growth of ALA businesses in various aspects.
2. Status of shares held by the SBI Group before and after the share transfer
(1) Holding ratio before the transfer 79.15% (2) Holding ratio after the transfer 73.32%
3. Future outlook
As a result of this transfer, consolidated extraordinary income of approximately 4.2 billion yen is expected to be recorded for the fiscal year ending March 2012.
* About 5-aminolevulinic acid (ALA):
An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SBI HOLDINGS INC
01/06 SBI : Kubota Pharmaceutical Holdings Signs Letter of Intent to Form a Joint Vent..
01/04 SBI : and IBM Japan to Launch Joint Venture Offering Support to Regional Financi..
2016 SBI : Kubota Pharmaceutical Signs LOI to Form Joint Venture with SBI Holdings
2016 SBI : Kubota, SBI Holdings to form JV for ophthalmic drugs and devices developme..
2016 SBI : Kubota Pharmaceutical Holdings Signs Letter of Intent to Form a Joint Vent..
2016 SBI : Treasure Data Secures USD25 Million in Series C Funding
2016 SBI : Japan`s SBI launches Islamic fund for Southeast Asia
2016 SBI : Official Launch of “The Japan Bank Consortium to Central Provide Dom..
2016 SBI : Exclusive License Agreement Concluded with Neopharma on the Therapeutic Dr..
2016 SBI : Biotech’s Licensed Product, an Anti-ILT7 Antibody (MEDI7734*) Has Ac..
More news
Sector news : Diversified Investment Services
01/10DJMcDonald's Pulls Back In China With Deal -- WSJ
01/09DJMcDonald's Sells Controlling Stake in China Business Valued at Up to $2.08 Bi..
01/09 Morgan Stanley, UBS to raise stakes in China securities JVs to 49 percent - s..
01/09DJMcDonald's Sells Controlling Stake in China Business Valued at Up to $2.08 Bi..
01/09DJMcDonald's Sells Controlling Stake in China Business Valued at Up to $2.08 Bi..
More sector news : Diversified Investment Services
Advertisement
Financials ( JPY)
Sales 2017 255 500 M
EBIT 2017 -
Net income 2017 24 825 M
Debt 2017 -
Yield 2017 1,93%
P/E ratio 2017 13,47
P/E ratio 2018 12,63
Capi. / Sales 2017 1,36x
Capi. / Sales 2018 1,30x
Capitalization 348 520 M
More Financials
Chart SBI HOLDINGS INC
Duration : Period :
SBI Holdings Inc Technical Analysis Chart | 8473 | JP3436120004 | 4-Traders
Full-screen chart
Technical analysis trends SBI HOLDINGS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1 270  JPY
Spread / Average Target -18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshitaka Kitao President & Representative Director
Tomoya Asakura Director & Senior Managing Executive Officer
Shumpei Morita Director & Managing Executive Officer
Kiyoshi Nagano Independent Outside Director
Keiji Watanabe Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SBI HOLDINGS INC2.96%3 043
CITIC LTD1.44%43 223
CREDIT SUISSE GROUP AG10.34%33 393
MACQUARIE GROUP LTD-1.41%21 922
NATIXIS4.59%18 712
CHINA HUARONG ASSET MA..4.66%14 664
More Results